Photo: Depositphotos
Apr 13, 2025, 06:03
Results from the multicenter PALMARES-2 study
Flavia Jacobs, Medical Research Fellow at Institute Jules Bordet, recently shared on LinkedIn:
“Don’t miss this paper!
First real-world head-to-head comparison of palbociclib, ribociclib and abemaciclib in HR+/HER2- advanced breast cancer — results from the multicenter PALMARES2 study, now published in Annals of Oncology.
- Abemaciclib and ribociclib showed better rwPFS than palbociclib overall.
- Abemaciclib was more effective than palbociclib in endocrine-sensitive patients.
- Abemaciclib and ribociclib were more effective than palbociclib in premenopausal, luminal B-like and de novo cases.
- Palbociclib had similar outcomes in older and bone-only patients.
Congrats to Leonardo Provenzano for leading this huge project. Super proud to be part of this great collaborative effort!”
“Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study.”
Authors: Leonardo Provenzano et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 14, 2025, 13:49
Apr 14, 2025, 13:47
Apr 14, 2025, 13:40
Apr 14, 2025, 13:36
Apr 14, 2025, 13:31
Apr 14, 2025, 13:19